tailieunhanh - Báo cáo y học: " Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia: a case report"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia: a case report | JOURNAL OF MEDICAL Sr CASE REPORTS Case report Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia a case report 1 ATcs-roT 1 r o T pcini1 PpnofM Roeei1 TdTilzoAric1 v_jX X X XX X X- LX LLL X V SX JXXXcd. X-f L XXX XvXđrX X . J Xv jssx XvX XXXcXX J . Jv xc Nicolo Patroniti2 Giuseppe Foti2 and Ettore Biagi1 Addresses Department of Pediatric Hematology San Gerardo Hospital Monza University of Milan-Bicocca Milan Italy and 2Department of Intensive Care San Gerardo Hospital Monza University of Milan-Bicocca Milan Italy Email CB - VL - MRR - MJ - momcilo@ NP - GF - gfoti@ EB - Corresponding author Open Access Published 1 April 2009 Received 21 May 2008 Journal of Medical Case Reports 2009 3 6443 doi 1752-1947-3-6443 Accepted 1 January 2009 This article is available from http jmedicalcasereports article view 3 4 6443 2009 Beretta et al licensee Cases Network Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Autoimmune hemolytic anemia in children younger than 2 years of age is usually characterized by a severe course with a mortality rate of approximately 10 . The prolonged immunosuppression following specific treatment may be associated with a high risk of developing severe infections. Recently the use of monoclonal antibodies rituximab has allowed sustained remissions to be obtained in the majority of pediatric patients with refractory autoimmune hemolytic anemia. Case presentation We describe the case of